A Multicenter, Open-Label, Phase 2 Study to Evaluate the Safety and Efficacy of NKTR-102 When Given on a Q14 Day or a Q21 Day Schedule in Patients With Metastatic or Locally Advanced Platinum-Resistant Ovarian Cancer

Inclusion Criteria:

1. Histologically or cytologically confirmed diagnosis of epithelial ovarian cancer,
primary peritoneal cancer or fallopian tube cancer

2. Inoperable metastatic or locally advanced ovarian cancer

3. Platinum-resistant ovarian cancer defined as progression by RECIST within 6 months of
last dose of most recent platinum drug

4. Platinum-resistant patients who have progressed after receiving PLD
(Doxil/Caelyx)therapy in a platinum-resistant setting or who otherwise unable to
receive PLD therapy.

5. Diseases must be measurable as defined by RECIST in at least 1 lesion not previously
irradiated.

6. ECOG performance score of 0 or 1.

7. Adequate organ and bone marrow functions at Screening.

Exclusion Criteria:

1. Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for
nitrosoureas or mitomycin C) and have not recovered to NCI-CTCAE grade 1 toxicity
prior to Day 1 of Cycle 1

2. Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle 1 or
minor surgery within 2 weeks prior to Day 1 of Cycle 1

3. Patients who have received CYP3A4 inducers or inhibitors.

4. Patients who have received any treatment with a camptothecin derivative (eg.
irinotecan, topotecan, SN38 investigational agents, etc.).

5. Patients with CNS metastases.